SCHEMBL2346765

SCHEMBL2346765

Cc1noc(NC(=O)N2CCC3(CC2)CC(F)(c2cccc(Cl)c2)C3)c1C

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
CYP3A4 P08684 5/20 0.41
ALDH1A1 P00352 3/20 0.41
CYP2D6 P10635 3/20 0.41
EDNRB P24530 1/20 0.40
EDNRA P25101 1/20 0.40
CYP1A2 P05177 6/20 0.39
NPY5R Q15761 1/20 0.38
TSHR P16473 1/20 0.37
RECQL P46063 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
EPHX2 P34913 2/20 0.37
LMNA P02545 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2340268 0.85 EPHX2 (0.45) CYP3A4ALDH1A1CYP2D6EPHX2
SCHEMBL2341595 0.80 CYP3A4 (0.42) KMT2AMEN1CYP3A4ALDH1A1CYP2D6
SCHEMBL2344713 0.79 P2RY1 (0.42) KMT2AMEN1CYP3A4ALDH1A1CYP2D6
SCHEMBL2341108 0.77 P2RY1 (0.41) CYP3A4ALDH1A1CYP2D6CYP1A2TSHR
SCHEMBL2343479 0.76 CYP3A4 (0.39) KMT2AMEN1CYP3A4ALDH1A1CYP2D6
SCHEMBL2426916 0.75 TRPM8 (0.35) CYP3A4ALDH1A1CYP2D6EDNRBEDNRA
SCHEMBL2432360 0.75 TRPM8 (0.35) CYP3A4ALDH1A1CYP2D6EDNRBEDNRA
SCHEMBL2431263 0.74 MGLL (0.41) KMT2AMEN1CYP3A4ALDH1A1CYP2D6
SCHEMBL2345262 0.73 CYP3A4 (0.41) KMT2ACYP3A4ALDH1A1CYP2D6EDNRB
SCHEMBL2340195 0.73 P2RY1 (0.42) CYP3A4ALDH1A1CYP2D6CYP1A2EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2358704-A1 7-azaspiro [3.5]nonane-7-carboxamide compounds as modulators of fatty acid amide hydrolase Pfizer Inc. (US) 2011-08-24 EP claimed
US-20100113465-A1 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS PFIZER INC. 2010-05-06 US claimed
WO-2010049841-A1 7-AZASPIRO [3.5] NONANE-7-CARBOXAMIDE COMPOUNDS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE PFIZER INC. (US) 2010-05-06 WO claimed
US-20100113465-A1 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS PFIZER INC. 2010-05-06 US disclosed
US-20100113465-A1 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS PFIZER INC. 2010-05-06 US disclosed
US-20100113465-A1 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS PFIZER INC. 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113465-A1 7-AZASPIRO[3.5]NONANE-7-CARBOXAMIDE COMPOUNDS FAAH, FAAH2, APEH KMT2A 717/4885MEN1 1724/4885CYP3A4 912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.